
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis</strong></summary>
            <div>
                <ul><li>Authors: Jolien Schol, Lucas Wauters, Ram Dickman, et al.</li><li>Journal: United European Gastroenterology Journal</li><li>Publication Date: 2021</li><li>DOI: 10.1002/ueg2.12060</li><li>Focus: European expert consensus on definition, symptoms, pathophysiology, diagnosis, and management of gastroparesis.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What are the cardinal symptoms of gastroparesis according to the European consensus?</li><li>2. What percentage of patients with idiopathic gastroparesis also fulfill the ROME III criteria for functional dyspepsia?</li><li>3. What is the estimated incidence of gastroparesis per 100,000 person-years in Olmsted County, Minnesota?</li><li>4. Which diagnostic test is considered the gold standard for assessing gastric emptying in gastroparesis?</li><li>5. Which classes of medications were considered appropriate therapies for gastroparesis by the consensus panel?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>1. Definitions and Symptom Descriptors</strong></summary>
            <div>
                <ul><li>Gastroparesis: Symptoms + delayed GE in absence of mechanical obstruction.</li><li>Nausea and vomiting are cardinal symptoms.</li><li>Dyspeptic symptoms (postprandial fullness, early satiation, epigastric pain, bloating, belching) often present.</li></ul>
                
        <details>
            <summary><strong>1.1 Definition of Gastroparesis</strong></summary>
            <div>
                <ul><li>Symptoms associated w/ delayed GE in absence of mechanical obstruction.</li><li>Overall agreement: 100% (A+ 60%, A 40%).</li><li>GRADE A.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>1.2 Disturbed Gastric Motor Function</strong></summary>
            <div>
                <ul><li>Symptoms associated w/ severely disturbed gastric motor function in absence of mechanical obstruction.</li><li>Overall agreement: 85% (A+ 48%, A 38%, A−13%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>1.3 Cardinal Symptoms</strong></summary>
            <div>
                <ul><li>Nausea and vomiting are cardinal symptoms.</li><li>Overall agreement: 95% (A+ 68%, A 28%, A−5%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>1.4 Dyspeptic Symptoms</strong></summary>
            <div>
                <ul><li>Postprandial fullness, early satiation, epigastric pain, bloating, and belching often present.</li><li>Overall agreement: 95% (A+ 60%, A 35%, A−5%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>1.5 Symptom Overlap</strong></summary>
            <div>
                <ul><li>Symptoms overlap mainly w/ PDS, less w/ EPS symptoms of FD.</li><li>Overall agreement: 90% (A+ 45%, A 45%, A−8%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Additional Details</strong></summary>
            <div>
                <ul><li>Delayed GE should be based on established reference range.</li><li>Asymptomatic delayed GE may be present, especially in diabetics.</li><li>Symptoms overlap w/ FD (Rome IV criteria).</li></ul>
                
        <details>
            <summary><strong>Symptoms and GE</strong></summary>
            <div>
                <ul><li>Association ≠ causation; symptoms may be related to other gastric sensorimotor dysfunctions.</li><li>Symptoms present for ≥3 months for diagnosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Symptom Prevalence</strong></summary>
            <div>
                <ul><li>Nausea: &gt;95%, associated w/ severity of delay.</li><li>Vomiting: Associated w/ nausea and more severe delay.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Overlap with FD</strong></summary>
            <div>
                <ul><li>US study: 86% of idiopathic gastroparesis patients fulfilled ROME III criteria for FD.</li><li>PDS: 91%, EPS: 1.2%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pain and Bloating</strong></summary>
            <div>
                <ul><li>Pain less prevalent in studies excluding opioid users.</li><li>Bloating common in functional digestive disorders and gastroparesis.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>2. Epidemiology and Risk Factors</strong></summary>
            <div>
                <ul><li>Epidemiology not established due to GE testing requirements.</li><li>Diabetes, gastric surgery, neurological disorders, connective tissue diseases, and certain drugs are risk factors.</li></ul>
                
        <details>
            <summary><strong>2.1 Epidemiology</strong></summary>
            <div>
                <ul><li>Epidemiology not established due to GE testing requirements @ population level.</li><li>Overall agreement: 93% (A+ 40%, A 53%, A−8%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>2.2 Diabetes</strong></summary>
            <div>
                <ul><li>Diabetes is a risk factor.</li><li>Overall agreement: 100% (A+ 85%, A 12%, A−3%).</li><li>GRADE A.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>2.3 GI Infection</strong></summary>
            <div>
                <ul><li>Acute GI infection is a risk factor.</li><li>STATEMENT NOT ENDORSED, overall agreement 59%: A+ 18%, A 40%, A−33%, D−3%, D 5%, D+ 3%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>2.4 Gastric Resection/Surgery</strong></summary>
            <div>
                <ul><li>Partial gastric resection/vagotomy, bariatric surgery, antireflux surgery are risk factors.</li><li>Overall agreement: 85% (A+ 40%, A 45%, A−13%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>2.5 Hypothyroidism</strong></summary>
            <div>
                <ul><li>Hypothyroidism is a risk factor.</li><li>STATEMENT NOT ENDORSED, overall agreement 56%: A+ 23%, A 33%, A−28%, D−10%, D 8%, D+ 0%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>2.6 Neurological Disorders</strong></summary>
            <div>
                <ul><li>Some neurological disorders (e.g., Parkinson&#x27;s, MS) are associated w/ ↑ risk.</li><li>Overall agreement: 90% (A+ 33%, A 55%, A−10%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>2.7 Connective Tissue Diseases</strong></summary>
            <div>
                <ul><li>Some connective tissue diseases are associated w/ ↑ risk.</li><li>Overall agreement: 85% (A+ 43%, A 43%, A−13%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>2.8 Drugs</strong></summary>
            <div>
                <ul><li>Some drugs (e.g., opioids) are associated w/ ↑ risk.</li><li>Overall agreement: 100% (A+ 63%, A 38%, A−0%).</li><li>GRADE A.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Additional Details</strong></summary>
            <div>
                <ul><li>Analyses suggest low prevalence of formally diagnosed gastroparesis.</li><li>Olmsted County: Incidence 6.3/100,000 person-years, prevalence 24.2/100,000.</li><li>UK CPRD: Prevalence 13.8/100,000, incidence 1.9/100,000.</li></ul>
                
        <details>
            <summary><strong>Diabetes and Gastroparesis</strong></summary>
            <div>
                <ul><li>Idiopathic subgroup largest, high prevalence among diabetics (25-38%).</li><li>More frequent in type 1 vs type 2 DM.</li><li>Cumulative proportions over 10 years: Type 1 DM 5.2%, Type 2 DM 1.0%, controls 0.2%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Post-Infectious Gastroparesis</strong></summary>
            <div>
                <ul><li>Limited evidence suggests viral GI infections may cause postinfectious gastroparesis.</li><li>NIDDK cohort: 19% reported history suggestive of infectious etiology.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Postsurgical and Other Associations</strong></summary>
            <div>
                <ul><li>Postsurgical gastroparesis well established.</li><li>Hypothyroidism more frequent in gastroparesis (14% vs 8.2% in controls).</li><li>Several neurological and systemic disorders linked.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Opioids</strong></summary>
            <div>
                <ul><li>Opioids have greatest impact on GE.</li><li>Patients on opioids should not be considered gastroparesis unless confirmed off opioids.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>3. Impact of Gastroparesis</strong></summary>
            <div>
                <ul><li>Major source of healthcare costs and decreased quality of life.</li><li>Associated w/ psychosocial comorbidities (anxiety, depression).</li><li>Weight loss can be a consequence; eating disorders must be ruled out.</li></ul>
                
        <details>
            <summary><strong>3.1 Healthcare Costs</strong></summary>
            <div>
                <ul><li>Gastroparesis is a major source of healthcare costs.</li><li>Overall agreement: 85% (A+ 35%, A 50%, A−13%).</li><li>GRADE A.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>3.2 Life Expectancy</strong></summary>
            <div>
                <ul><li>Gastroparesis is associated with decreased life expectancy.</li><li>STATEMENT NOT ENDORSED, overall agreement 18%: A+ 5%, A 13%, A−38%, D−18%, D 23%, D+ 3%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>3.3 Self-Costs</strong></summary>
            <div>
                <ul><li>Gastroparesis is a major source of self-costs to patients.</li><li>STATEMENT NOT ENDORSED, overall agreement 65%: A+ 18%, A 48%, A−25%, D−3%, D 5%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>3.4 Work Productivity</strong></summary>
            <div>
                <ul><li>Gastroparesis is an important source of loss of work productivity.</li><li>STATEMENT NOT ENDORSED, overall agreement 78%: A+ 28%, A 50%, A−20%, D−0%, D 3%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>3.5 Quality of Life</strong></summary>
            <div>
                <ul><li>Gastroparesis is associated with a significant decrease in quality of life.</li><li>Overall agreement: 93% (A+ 68%, A 25%, A−8%).</li><li>GRADE A.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>3.6 Psychosocial Comorbidities</strong></summary>
            <div>
                <ul><li>Gastroparesis is associated with psychosocial comorbidities such as anxiety and depression.</li><li>Overall agreement: 83% (A+ 33%, A 50%, A−15%).</li><li>GRADE A.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>3.7 Weight Loss</strong></summary>
            <div>
                <ul><li>Weight loss can be a consequence of gastroparesis.</li><li>STATEMENT NOT ENDORSED, overall agreement 70%: A+ 40%, A 30%, A−28%, D−3%, D 0%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>3.8 Eating Disorders</strong></summary>
            <div>
                <ul><li>In case of weight loss, eating disorders must be ruled out.</li><li>Overall agreement: 98% (A+ 40%, A 58%, A−3%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>3.9 Healthcare Consulting - Symptom Driven</strong></summary>
            <div>
                <ul><li>Healthcare consulting behavior in gastroparesis is driven by symptom severity and impact.</li><li>STATEMENT NOT ENDORSED, overall agreement 78%: A+ 20%, A 58%, A−18%, D−3%, D 3%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>3.10 Healthcare Consulting - Psychosocial Driven</strong></summary>
            <div>
                <ul><li>Healthcare consulting behavior in gastroparesis is driven by psychosocial comorbidity.</li><li>STATEMENT NOT ENDORSED, overall agreement 40%: A+ 15%, A 25%, A−38%, D−8%, D 15%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>3.11 Healthcare Consulting - Access Driven</strong></summary>
            <div>
                <ul><li>Healthcare consulting behavior in gastroparesis is driven by access to the healthcare system.</li><li>STATEMENT NOT ENDORSED, overall agreement 54%: A+ 10%, A 43%, A−35%, D−8%, D 5%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Additional Details</strong></summary>
            <div>
                <ul><li>US data: 300% ↑ in gastroparesis-related admissions (1997-2013).</li><li>Emergency department visits more than doubled.</li></ul>
                
        <details>
            <summary><strong>Mortality</strong></summary>
            <div>
                <ul><li>Olmsted County: Overall survival ↓, higher mortality in diabetic vs idiopathic.</li><li>UK CPRD: Mortality rates higher in diabetic.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Self-Costs</strong></summary>
            <div>
                <ul><li>No data on self-cost, but may include OTC meds, alternative therapies, dietary adjustments.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Employment and Disability</strong></summary>
            <div>
                <ul><li>Small US cohort: 54% not employed, considered disabled.</li><li>Symptoms reduced daily activities in 67.5%, lowered income in 28.5%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Psychological Impact</strong></summary>
            <div>
                <ul><li>Anxiety and depression scores correlated w/ symptom severity.</li><li>Systematic review: Anxiety/depression in 24%, severe anxiety 12.4%, depression 23%, somatization 50%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Weight Loss and Eating Disorders</strong></summary>
            <div>
                <ul><li>Delayed GE not consistently associated w/ weight loss.</li><li>Eating disorder should be excluded, especially in adolescents.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Healthcare Consulting</strong></summary>
            <div>
                <ul><li>Driven by symptom severity and impact.</li><li>Regional differences in healthcare assistance.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>4. Pathophysiology of Gastroparesis</strong></summary>
            <div>
                <ul><li>No consensus on specific mechanisms.</li><li>Delayed GE, impaired gastric accommodation, hypersensitivity to distention, duodenal alterations, loss of ICCs/enteric nerves/vagus nerve function, gastric smooth muscle changes, H. pylori, altered acid secretion/peptide hormones/duodenal sensitivity/microbiota, anxiety, depression, disordered signal processing, and genetic factors were not endorsed as primary mechanisms.</li></ul>
                
        <details>
            <summary><strong>4.1 Delayed GE and Symptoms</strong></summary>
            <div>
                <ul><li>Delay in GE underlies symptom generation.</li><li>STATEMENT NOT ENDORSED, overall agreement 28%: A+ 10%, A 18%, A−48%, D−13%, D 10%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.2 Impaired Gastric Accommodation</strong></summary>
            <div>
                <ul><li>Impaired gastric accommodation contributes to symptom generation.</li><li>STATEMENT NOT ENDORSED, overall agreement 75%: A+ 20%, A 55%, A−20%, D−3%, D 3%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.3 Hypersensitivity to Gastric Distention</strong></summary>
            <div>
                <ul><li>Hypersensitivity to gastric distention contributes to symptom generation.</li><li>STATEMENT NOT ENDORSED, overall agreement 73%: A+ 18%, A 55%, A−20%, D−5%, D 3%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.4 Duodenal Mucosal Alterations</strong></summary>
            <div>
                <ul><li>Duodenal mucosal alterations (low grade inflammation, impaired permeability) are not implicated.</li><li>STATEMENT NOT ENDORSED, overall agreement 58%: A+ 10%, A 48%, A−25%, D−10%, D 8%, D+ 0%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.5 Loss of Interstitial Cells of Cajal (ICCs)</strong></summary>
            <div>
                <ul><li>Loss of ICCs is a pathophysiological mechanism.</li><li>STATEMENT NOT ENDORSED, overall agreement 60%: A+ 10%, A 50%, A−33%, D−0%, D 8%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.6 Loss of Enteric Nerves</strong></summary>
            <div>
                <ul><li>Loss of enteric nerves is a pathophysiological mechanism.</li><li>STATEMENT NOT ENDORSED, overall agreement 65%: A+ 5%, A 60%, A−30%, D−0%, D 5%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.7 Primary Changes in Gastric Smooth Muscle</strong></summary>
            <div>
                <ul><li>Primary changes in gastric smooth muscle are a pathophysiological mechanism.</li><li>STATEMENT NOT ENDORSED, overall agreement 53%: A+ 8%, A 45%, A−38%, D−5%, D 5%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.8 Loss of Vagus Nerve Function</strong></summary>
            <div>
                <ul><li>Loss of vagus nerve function is a pathophysiological mechanism.</li><li>STATEMENT NOT ENDORSED, overall agreement 68%: A+ 8%, A 60%, A−30%, D−3%, D 0%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.9 Helicobacter pylori Infection</strong></summary>
            <div>
                <ul><li>Helicobacter pylori infection is not a pathophysiological mechanism.</li><li>STATEMENT NOT ENDORSED, overall agreement 60%: A+ 18%, A 43%, A−23%, D−3%, D 13%, D+ 3%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.10 Altered Gastric Acid Secretion</strong></summary>
            <div>
                <ul><li>Altered gastric acid secretion is not a pathophysiological mechanism.</li><li>STATEMENT NOT ENDORSED, overall agreement 78%: A+ 23%, A 55%, A−15%, D−5%, D 3%, D+ 0%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.11 Altered Release of Peptide Hormones</strong></summary>
            <div>
                <ul><li>Altered release of peptide hormones is not a pathophysiological mechanism.</li><li>STATEMENT NOT ENDORSED, overall agreement 60%: A+ 5%, A 55%, A‐ 23%, D‐ 8%, D 8%, D+ 3%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.12 Increased Sensitivity to Duodenal Luminal Content</strong></summary>
            <div>
                <ul><li>Increased sensitivity to duodenal luminal content is not a pathophysiological mechanism.</li><li>STATEMENT NOT ENDORSED, overall agreement 70%: A+ 3%, A 68%, A‐ 18%, D‐ 8%, D 5%, D+ 0%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.13 Altered Duodenal Microbiota Composition</strong></summary>
            <div>
                <ul><li>Altered duodenal microbiota composition is not a pathophysiological mechanism.</li><li>STATEMENT NOT ENDORSED, overall agreement 59%: A+ 10%, A 48%, A−25%, D−10%, D 5%, D+ 3%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.14 Anxiety</strong></summary>
            <div>
                <ul><li>Anxiety is a pathophysiological factor.</li><li>STATEMENT NOT ENDORSED, overall agreement 43%: A+ 10%, A 33%, A−28%, D−15%, D 13%, D+ 3%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.15 Depression</strong></summary>
            <div>
                <ul><li>Depression is a pathophysiological factor.</li><li>STATEMENT NOT ENDORSED, overall agreement 43%: A+ 8%, A 35%, A−28%, D−13%, D 15%, D+ 3%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.16 Disordered Processing of Signals</strong></summary>
            <div>
                <ul><li>Disordered processing of incoming signals from the gastroduodenal region is a pathophysiological mechanism.</li><li>STATEMENT NOT ENDORSED, overall agreement 58%: A+ 5%, A 53%, A−25%, D−10%, D 5%, D+ 3%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>4.17 Genetic Factors</strong></summary>
            <div>
                <ul><li>Genetic factors determine susceptibility to gastroparesis.</li><li>STATEMENT NOT ENDORSED, overall agreement 55%: A+ 0%, A 55%, A−30%, D−8%, D 8%, D+ 0%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Additional Details</strong></summary>
            <div>
                <ul><li>Symptoms are poor predictors of GE rate or response to prokinetics.</li><li>More severe symptom burden may be associated w/ more severely delayed emptying, but inconsistent.</li></ul>
                
        <details>
            <summary><strong>Idiopathic Gastroparesis</strong></summary>
            <div>
                <ul><li>Barostat studies: 43% impaired accommodation, 29% hypersensitivity to distension.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diabetic Gastroparesis</strong></summary>
            <div>
                <ul><li>↓ gastric accommodation and sensory thresholds.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Histopathology</strong></summary>
            <div>
                <ul><li>Animal model and biopsies showed ↓ density of ICCs.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gastric Smooth Muscle</strong></summary>
            <div>
                <ul><li>Conflicting data on fibrotic and inflammatory changes.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Vagal Dysfunction</strong></summary>
            <div>
                <ul><li>Diabetic gastroparesis more frequently associated w/ vagal dysfunction.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Other Factors</strong></summary>
            <div>
                <ul><li>No consistent correlation between H. pylori and GE rate.</li><li>No studies evaluated gastric acid secretion, duodenal sensitivity, or microbiota composition.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Psychological Factors</strong></summary>
            <div>
                <ul><li>Anxiety and depression related to symptom severity and hospitalization rates, not etiology or GE rates.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Central Nervous System</strong></summary>
            <div>
                <ul><li>Hypersensitivity to gastric distension present, likely involves altered processing of incoming signals.</li><li>fMRI study showed altered connectivity of the insula.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Genetic Factors</strong></summary>
            <div>
                <ul><li>Long repeat polymorphism in heme oxygenase (HO1) associated w/ worse outcomes.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>5. Diagnosis</strong></summary>
            <div>
                <ul><li>Upper GI endoscopy and abnormal GE test are mandatory.</li><li>Scintigraphic GE assessment and breath test are valid.</li><li>Small bowel obstruction can be ruled out through imaging.</li></ul>
                
        <details>
            <summary><strong>5.1 Upper GI Endoscopy</strong></summary>
            <div>
                <ul><li>Upper GI endoscopy is mandatory.</li><li>Overall agreement: 93% (A+ 75%, A 18%, A−8%).</li><li>GRADE A.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>5.2 Food in Fasting State</strong></summary>
            <div>
                <ul><li>Presence of food in fasting state during endoscopy is diagnostic.</li><li>STATEMENT NOT ENDORSED, overall agreement 40%: A+ 10%, A 30%, A−30%, D−10%, D 15%, D+ 5%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>5.3 Abnormal GE Test</strong></summary>
            <div>
                <ul><li>An abnormal GE test is mandatory.</li><li>Overall agreement: 95% (A+ 80%, A 15%, A−3%).</li><li>GRADE A.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>5.4 Scintigraphic GE Assessment</strong></summary>
            <div>
                <ul><li>Scintigraphic GE assessment is a valid test.</li><li>Overall agreement: 98% (A+ 88%, A 10%, A−3%).</li><li>GRADE A.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>5.5 Breath Test Assessment</strong></summary>
            <div>
                <ul><li>Breath test assessment is a valid test.</li><li>Overall agreement: 95% (A+ 60%, A 35%, A−0%).</li><li>GRADE A.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>5.6 Wireless Motility Capsule (WMC)</strong></summary>
            <div>
                <ul><li>Wireless motility capsule assessment is a valid test.</li><li>STATEMENT NOT ENDORSED, overall agreement 33%: A+ 8%, A 25%, A−48%, D−5%, D 15%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>5.7 Gastric Ultrasound</strong></summary>
            <div>
                <ul><li>Gastric ultrasound assessment is a valid test.</li><li>STATEMENT NOT ENDORSED, overall agreement 18%: A+ 5%, A 13%, A−48%, D−5%, D 28%, D+ 3%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>5.8 Rule Out Small Bowel Obstruction</strong></summary>
            <div>
                <ul><li>Small bowel obstruction can be ruled out through imaging.</li><li>Overall agreement: 88% (A+ 25%, A 63%, A−10%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Additional Details</strong></summary>
            <div>
                <ul><li>EGD is prerequisite to exclude gastric outlet obstruction.</li><li>Food retention during EGD after overnight fast has been used as a sign, but poor sensitivity.</li></ul>
                
        <details>
            <summary><strong>GE Scintigraphy</strong></summary>
            <div>
                <ul><li>Gold standard: 99mTechnetium-labeled low-fat egg meal, imaging at 0, 1, 2, and 4 h.</li><li>Fairly reproducible.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>GE Breath Test (GEBT)</strong></summary>
            <div>
                <ul><li>FDA-approved, non-invasive, uses 13C.</li><li>High correlation w/ scintigraphy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Wireless Motility Capsule (WMC)</strong></summary>
            <div>
                <ul><li>FDA-approved.</li><li>Sensitivity 59-86%, specificity 64-81% compared to scintigraphy.</li><li>Pitfall: indigestible solid, empties w/ phase 3 migrating motor complexes.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gastric Ultrasonography</strong></summary>
            <div>
                <ul><li>Noninvasive, safe, cheap, widely available.</li><li>Unable to distinguish solid and liquid components.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Small Bowel Obstruction</strong></summary>
            <div>
                <ul><li>Abdominal radiography (accuracy 50-86%).</li><li>CT scanning most accurate.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>6. Treatment</strong></summary>
            <div>
                <ul><li>Dietary adjustments, dopamine-2 antagonists, and 5-HT4 agonists are considered appropriate therapies.</li><li>No consensus on PPIs, other antiemetics/prokinetics, neuromodulators, complimentary/psychological/invasive therapies.</li></ul>
                
        <details>
            <summary><strong>6.1 Dietary Adjustments</strong></summary>
            <div>
                <ul><li>Dietary adjustments are useful.</li><li>Overall agreement: 85% (A+ 35%, A 50%, A−15%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.2 PPI as First-Line Therapy</strong></summary>
            <div>
                <ul><li>PPI therapy is the most appropriate first line therapy.</li><li>STATEMENT NOT ENDORSED, overall agreement 0%: A+ 0%, A 0%, A−18%, D−13%, D 55%, D+ 15%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.3 PPI Effectiveness</strong></summary>
            <div>
                <ul><li>PPI therapy is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 10%: A+ 0%, A 10%, A−15%, D−23%, D 48%, D+ 5%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.4 PPI for Reflux Symptoms</strong></summary>
            <div>
                <ul><li>PPI therapy is only effective for associated reflux symptoms.</li><li>STATEMENT NOT ENDORSED, overall agreement 70%: A+ 15%, A 55%, A−25%, D−3%, D 3%, D+ 0%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.5 Antiemetic as First-Line Therapy</strong></summary>
            <div>
                <ul><li>Antiemetic therapy is the most appropriate first line therapy.</li><li>STATEMENT NOT ENDORSED, overall agreement 43%: A+ 5%, A 38%, A−33%, D−10%, D 15%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.6 Antiemetic Effectiveness</strong></summary>
            <div>
                <ul><li>Antiemetic therapy is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 48%: A+ 8, A 40%, A−45%, D−3%, D 5%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.7 Dopamine-2 Antagonists</strong></summary>
            <div>
                <ul><li>Dopamine-2 antagonists are effective.</li><li>Overall agreement: 86% (A+ 23%, A 63%, A−15%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.8 5-HT3 Antagonists</strong></summary>
            <div>
                <ul><li>5-HT3 antagonists are effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 63%: A+ 5%, A 58%, A−33%, D−5%, D 0%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.9 NK1 Antagonists</strong></summary>
            <div>
                <ul><li>NK1 antagonists are effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 40%: A+ 5%, A 35%, A−48%, D−3%, D 10%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.10 Prokinetic as First-Line Therapy</strong></summary>
            <div>
                <ul><li>Prokinetic therapy is the most appropriate first line therapy.</li><li>STATEMENT NOT ENDORSED, overall agreement 78%: A+ 38%, A 40%, A−15%, D−0%, D 8%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.11 Prokinetic Effectiveness</strong></summary>
            <div>
                <ul><li>Prokinetic therapy is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 75%: A+ 18%, A 58%, A−23%, D−0%, D 3%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.12 Prokinetic Efficacy and GE Rate</strong></summary>
            <div>
                <ul><li>The efficacy of prokinetics is not related to their enhancement of GE rate.</li><li>STATEMENT NOT ENDORSED, overall agreement 55%: A+ 10%, A 45%, A−35%, D−5%, D 5%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.13 Itopride Effectiveness</strong></summary>
            <div>
                <ul><li>Itopride is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 35%: A+ 5%, A 30%, A−23%, D−23%, D 20%, D+ 0%. GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.14 5-HT4 Agonists</strong></summary>
            <div>
                <ul><li>5-HT4 agonists are effective.</li><li>Overall agreement: 85% (A+ 18%, A 68%, A−15%).</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.15 Motilin-Receptor Agonists</strong></summary>
            <div>
                <ul><li>Motilin-receptor agonists are effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 58%: A+ 10%, A 48%, A−40%, D−0%, D 0%, D+ 3%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.16 Ghrelin-Receptor Agonists</strong></summary>
            <div>
                <ul><li>Ghrelin-receptor agonists are effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 40%: A+ 8%, A 33%, A−53%, D−3%, D 3%, D+ 3%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.17 Tricyclic Antidepressants</strong></summary>
            <div>
                <ul><li>Tricyclic antidepressants are effective.</li><li>STATEMENT NOTNOT ENDORSED, overall agreement 8%: A+ 3%, A 5%, A−25%, D−23%, D 40%, D+ 5%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.18 Tricyclic Antidepressants (Negative)</strong></summary>
            <div>
                <ul><li>Tricyclic antidepressants are not effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 65%: A+ 8%, A 53%, A−15%, D−13%, D 13%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.19 SSRI Effectiveness</strong></summary>
            <div>
                <ul><li>SSRI are effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 10%: A+ 0%, A 10%, A−18%, D−20%, D 50%, D+ 3%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.20 SSRI Negative</strong></summary>
            <div>
                <ul><li>SSRI are not effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 63%: A+ 10%, A 53%, A−13%, D−13%, D 13%, D+ 0%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.21 SNRI Effectiveness</strong></summary>
            <div>
                <ul><li>SNRI are effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 0%: A+ 0%, A 0%, A−13%, D−30%, D 55%, D+ 3%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.22 SNRI Negative</strong></summary>
            <div>
                <ul><li>SNRI are not effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 63%: A+ 10%, A 53%, A−25%, D−5%, D 8%, D+ 0%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.23 Mirtazapine Effectiveness</strong></summary>
            <div>
                <ul><li>Mirtazapine is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 35%: A+ 5%, A 30%, A−50%, D−5%, D 10%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.24 5-HT1A Agonists</strong></summary>
            <div>
                <ul><li>5-HT1A agonists are effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 15%: A+ 0%, A 15%, A−20%, D−30%, D 33%, D+ 3%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.25 5-HT1A Agonists Negative</strong></summary>
            <div>
                <ul><li>5-HT1A agonists are not effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 40%: A+ 5%, A 35%, A−33%, D−5%, D 23%, D+ 0%.</li><li>GRADE C</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.26 Gastric Electrical Stimulation (GES)</strong></summary>
            <div>
                <ul><li>Gastric electrical stimulation (GES) is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 38%: A+ 15%, A 23%, A−38%, D−15%, D 10%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.27 Pyloric Botulinum Toxin Injection</strong></summary>
            <div>
                <ul><li>Pyloric botulinum toxin injection is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 13%: A+ 0%, A 13%, A−38%, D−20%, D 25%, D+ 5%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.28 Pyloric Myotomy</strong></summary>
            <div>
                <ul><li>Pyloric myotomy is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 28%: A+ 5%, A 23%, A−43%, D−10%, D 20%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.29 Partial/Subtotal Gastrectomy</strong></summary>
            <div>
                <ul><li>Partial or subtotal gastrectomy is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 18%: A+ 3%, A 15%, A−38%, D−8%, D 33%, D+ 5%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.30 Surgical/Pyloric Therapies and Dumping Syndrome</strong></summary>
            <div>
                <ul><li>Surgical or pyloric targeting therapies may induce dumping syndrome.</li><li>STATEMENT NOT ENDORSED, overall agreement 35%: A+ 5%, A 30%, A−40%, D−8%, D 18%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.31 H. Pylori Eradication</strong></summary>
            <div>
                <ul><li>H. Pylori-infected gastroparesis patients should receive eradication therapy.</li><li>STATEMENT NOT ENDORSED, overall agreement 5%: A+ 20%, A 55%, A−18%, D−0%, D 8%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.32 Herbal Therapies Effectiveness</strong></summary>
            <div>
                <ul><li>Herbal therapies are effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 10%: A+ 0%, A 10%, A−45%, D−20%, D 23%, D+ 3%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.33 Herbal Therapies Negative</strong></summary>
            <div>
                <ul><li>Herbal therapies are not effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 23%: A+ 3%, A 20%, A−23%, D−38%, D 15%, D+ 3%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.34 Iberogast (STW-5)</strong></summary>
            <div>
                <ul><li>Iberogast (STW-5) is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 20%: A+ 8%, A 13%, A−33%, D−13%, D 35%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.35 Hypnotherapy</strong></summary>
            <div>
                <ul><li>Hypnotherapy is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 8%: A+ 0%, A 8%, A−20%, D−25%, D 43%, D+ 5%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.36 Cognitive Behavioral Therapy</strong></summary>
            <div>
                <ul><li>Cognitive behavioral therapy is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 15%: A+ 0%, A 15%, A−23%, D−18%, D 40%, D+ 5%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.37 Acupuncture</strong></summary>
            <div>
                <ul><li>Acupuncture is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 3%: A+ 0%, A 3%, A−43%, D−5%, D 45%, D+ 5%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.38 Mindfulness</strong></summary>
            <div>
                <ul><li>Mindfulness is effective.</li><li>STATEMENT NOT ENDORSED, overall agreement 13%: A+ 0%, A 13%, A−10%, D−25%, D 48%, D+ 5%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>6.39 Nutritional Support</strong></summary>
            <div>
                <ul><li>In case of severe weight loss or intractable vomiting, nutritional support may be needed.</li><li>Overall agreement: 98% (A+ 53%, A 45%, A−3%).</li><li>GRADE B.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Additional Details</strong></summary>
            <div>
                <ul><li>Small particle size diet reduces gastroparesis and reflux symptoms in diabetic gastroparesis.</li><li>Nutritional support and dietician engagement can correct calorie deficiencies.</li></ul>
                
        <details>
            <summary><strong>PPIs</strong></summary>
            <div>
                <ul><li>Efficacy not addressed in controlled trials.</li><li>High intake in gastroparesis patients (≥70%), &gt;50% have overlapping GERD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Antiemetics</strong></summary>
            <div>
                <ul><li>Recommended as first-line, but no formal studies establishing efficacy.</li><li>Metoclopramide (dopamine-2 antagonist) approved in US, carries black box warning.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Metoclopramide Nasal Spray</strong></summary>
            <div>
                <ul><li>Phase 2 RCT: 10/14 mg doses did not significantly reduce symptom scores vs placebo.</li><li>Significant effect in females only.</li><li>Adverse events: headache, fatigue, dysgeusia.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Domperidone</strong></summary>
            <div>
                <ul><li>Peripherally acting dopamine-2 antagonist, ↓ nausea, ↑ GE.</li><li>Less likely to cause extrapyramidal side effects.</li><li>Associated w/ QTc prolongation.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>5-HT3 Antagonists</strong></summary>
            <div>
                <ul><li>Ondansetron, granisetron have antiemetic properties, but controlled studies lacking.</li><li>Open label study suggested efficacy of granisetron transdermal patches.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Aprepitant</strong></summary>
            <div>
                <ul><li>Neurokinin-1 receptor antagonist, efficacious in some patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Prokinetic Agents</strong></summary>
            <div>
                <ul><li>Enhance symptoms and improve GE rate.</li><li>Disparity: relationship between symptom improvement and GE rate is poor.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Itopride</strong></summary>
            <div>
                <ul><li>Combined dopamine-2 antagonist and cholinesterase inhibitor.</li><li>Small study: no significant effect in diabetic gastroparesis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>5-HT4 Agonists</strong></summary>
            <div>
                <ul><li>Cisapride withdrawn due to cardiologic side effects.</li><li>Tegaserod temporarily withdrawn.</li><li>Prucalopride: one study showed efficacy, another failed.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Motilin-Receptor Agonists</strong></summary>
            <div>
                <ul><li>Camicinal, RaQualia, Mitemcinal studied.</li><li>Macrolide antibiotics (erythromycin) also act on motilin receptor, but risks and side effects exist.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Ghrelin-Receptor Agonists</strong></summary>
            <div>
                <ul><li>TZP-101, TZP-102, RM-131 (relamorelin) studied.</li><li>Phase 3 program for relamorelin discontinued.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Neuromodulators</strong></summary>
            <div>
                <ul><li>Nortriptyline showed no gain over placebo.</li><li>Amitriptyline appeared beneficial in ulcer-like FD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Mirtazapine</strong></summary>
            <div>
                <ul><li>Open label study: improvement in nausea, vomiting, and appetite.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gastric Electrical Stimulation (GES)</strong></summary>
            <div>
                <ul><li>Uncontrolled studies reported efficacy.</li><li>Recent sham-controlled study reported improvement on vomiting frequency, regardless of GE status.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pyloric Botulinum Toxin Injection</strong></summary>
            <div>
                <ul><li>Open-label studies reported short-term efficacy.</li><li>Subsequent controlled trials failed to demonstrate improvement.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pyloric Myotomy</strong></summary>
            <div>
                <ul><li>Open-label studies reported short and midterm efficacy.</li><li>No controlled validating studies.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Gastrectomy</strong></summary>
            <div>
                <ul><li>Symptomatic improvement reported in 43-90%, morbidity up to 40%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>H. Pylori Eradication</strong></summary>
            <div>
                <ul><li>Two studies suggested eradication enhanced GE rate, but used nonvalidated tests.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Herbal Therapies</strong></summary>
            <div>
                <ul><li>Lack of data on effects in gastroparesis.</li><li>STW-5 (Iberogast) did not alter GE rate.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Psychological Therapies</strong></summary>
            <div>
                <ul><li>Lack of specific reports in gastroparesis patients.</li><li>Acupuncture: Cochrane review found higher symptom improvement rates, but uncertain conclusion.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Nutritional Support</strong></summary>
            <div>
                <ul><li>Enteral or parenteral nutrition for refractory gastroparesis w/ weight loss/nutritional deficiencies.</li><li>Jejunal tube feeding advocated for long-term support.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>7. Prognosis of Gastroparesis</strong></summary>
            <div>
                <ul><li>Prognosis depends on the cause.</li><li>No consensus on unfavorable long-term prognosis or increased mortality.</li></ul>
                
        <details>
            <summary><strong>7.1 Long-Term Prognosis</strong></summary>
            <div>
                <ul><li>The long-term prognosis is unfavorable.</li><li>STATEMENT NOT ENDORSED, overall agreement 35%: A+ 15%, A 20%, A−28%, D−23%, D 15%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>7.2 Prognosis and Cause</strong></summary>
            <div>
                <ul><li>The prognosis depends on the cause.</li><li>Overall agreement: 88% (A+ 33%, A+ 54%, A 10%, A−3%).</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>7.3 Life Expectancy</strong></summary>
            <div>
                <ul><li>Life expectancy is shortened.</li><li>STATEMENT NOT ENDORSED, overall agreement 25%: A+ 5%, A 20%, A−35%, D−18%, D 23%, D+ 0%.</li><li>GRADE B</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Additional Details</strong></summary>
            <div>
                <ul><li>Symptoms and GE delay persist for several years in majority of patients.</li><li>NIDDK consortium: some symptom improvement at 48 weeks, but not from 48 to 192 weeks.</li></ul>
                
        <details>
            <summary><strong>Factors Associated with Reduced Symptoms</strong></summary>
            <div>
                <ul><li>Male sex, age &gt;50, initial infectious prodrome, antidepressant use, 4-h gastric retention &gt;20%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Factors Associated with Lack of Improvement</strong></summary>
            <div>
                <ul><li>Overweight/obesity, smoking, pain modulators, moderate-severe abdominal pain, severe GERD, moderate-severe depression.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Life Expectancy</strong></summary>
            <div>
                <ul><li>Conflicting data.</li><li>One study: delayed GE not related to mortality after adjustment for comorbidities.</li><li>Another: 7% died, 22% needed long-term feeding.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Mortality Risk</strong></summary>
            <div>
                <ul><li>Higher in diabetic vs idiopathic gastroparesis patients.</li><li>Population-based study: higher death rate due to cardiovascular comorbidity in diabetic patients.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Recommendations</strong></summary>
            <div>
                <ul><li>Gastroparesis: Symptoms + delayed GE in absence of mechanical obstruction, as well as severely disturbed gastric motor function.</li><li>Nausea and vomiting are the cardinal symptoms.</li><li>Diabetes, upper abdominal surgeries, neurological and connective tissue diseases, as well as the use of certain drugs are risk factors.</li><li>Gastroparesis is a major source of healthcare costs and associated with a significant decrease in quality of life and with psychosocial co-morbidities.</li><li>Upper GI endoscopy and an abnormal gastric emptying test are mandatory for diagnosis.</li><li>Dietary adjustments, dopamine-2 antagonists or 5-HT4 agonists can be used to manage symptoms.</li><li>In case of severe weight loss, nutritional support may be needed.</li><li>The long-term prognosis depends on the underlying cause.</li></ul>
                
        <details>
            <summary><strong>Key Consensus Points</strong></summary>
            <div>
                <ul><li>Cardinal symptom pattern: nausea/vomiting, w/ or w/o overlapping PDS.</li><li>Areas of uncertainty: underlying pathophysiological factors, therapy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Future Directions</strong></summary>
            <div>
                <ul><li>Advances in understanding pathophysiology may allow refinement of definitions and identification of more specific phenotypes.</li><li>Need for more therapeutic trials.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
